ZEN-3694 the first pan-BET inhibitor in Phase 3?

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

ZEN-3694 the first pan-BET inhibitor in Phase 3?

posted on Oct 25, 2019 09:48AM

In case you missed it in the slide deck.

Phase 2a mCRPC trial (AR inhibitor resistant) nearing completion. No data update but it must be going well for them to have had a meeting with the FDA and have received very positive FDA feedback for design of Phase 2b/3 registration enabling study to compare enzalutamide single agent vs. ZEN-3694+enzalutamide combo.